Carlo Tascini1, Vittorio Attanasio2, Marco Ripa3, Antonio Carozza4, Carlo Pallotto5, Mariano Bernardo6, Daniela Francisci7, Chiara Oltolini8, Giulia Palmiero9, Paolo Scarpellini10. 1. First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, via Bianchi snc, Naples, Italy. Electronic address: c.tascini@gmail.com. 2. First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, via Bianchi snc, Naples, Italy. Electronic address: rosa.zampino@tin.it. 3. Department of Infectious Disease, San Raffaele Hospital, via Stamira d'Ancona, Milan, Italy. Electronic address: ripa.marco@hsr.it. 4. UOSD Advanced Techniques in Cardiosurgery, Monaldi Hospital, AORN dei Colli, via Bianchi, snc, Naples, Italy. Electronic address: antonio.carozza@email.it. 5. Section of Infectious Diseases, Department of Medicine, University of Perugia, Piazzale Gambuli, 1, Perugia, Italy; UOC Infectious Diseases, San Donato Hospital, Azienda USL Toscana Sud Est, via Nenni, 22, Arezzo, Italy. Electronic address: pallottoc@gmail.com. 6. Microbiology and Virology Unit, Cotugno Hospital, AORN dei Colli, via Bianchi snc, Naples, Italy. Electronic address: marianobernardo@fastwebnet.it. 7. Section of Infectious Diseases, Department of Medicine, University of Perugia, Piazzale Gambuli, 1, Perugia, Italy. Electronic address: daniela.francisci@unipg.it. 8. Department of Infectious Disease, San Raffaele Hospital, via Stamira d'Ancona, Milan, Italy. Electronic address: oltolini.chiara@hsr.it. 9. First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, via Bianchi snc, Naples, Italy. Electronic address: giulia.palmiero@ospedalideicolli.it. 10. Department of Infectious Disease, San Raffaele Hospital, via Stamira d'Ancona, Milan, Italy. Electronic address: scarpellini.paolo@hsr.it.
Abstract
OBJECTIVES: Ceftobiprole is a relatively new cephalosporin with broad-spectrum activity and good tolerability. Despite its promising characteristics, to our knowledge, only two case reports, previously published also by some of us, is available concerning its administration for the treatment of infective endocarditis. Hereby we report our experience in this field. METHODS: All the patients with infective endocarditis treated with ceftobiprole were enrolled. RESULTS: 12 cases of endocarditis were treated with ceftobiprole, 11/12 in combination with daptomycin and 1/12 as monotherapy. Gram-positive bacteria were isolated in 12/12 patients; 3 cases were polymicrobial. Cure rate was 83% (10/12 patients). In 9/12 (75%) cases, patients were switched to ceftobiprole following failure of previous antimicrobial regimen. In 3/3 patients in which ceftobiprole was administered because of persistently positive blood culture, bacteraemia clearance was rapidly achieved. CONCLUSIONS: Ceftobiprole, especially in combination, could be a promising alternative treatment for infective endocarditis.
OBJECTIVES:Ceftobiprole is a relatively new cephalosporin with broad-spectrum activity and good tolerability. Despite its promising characteristics, to our knowledge, only two case reports, previously published also by some of us, is available concerning its administration for the treatment of infective endocarditis. Hereby we report our experience in this field. METHODS: All the patients with infective endocarditis treated with ceftobiprole were enrolled. RESULTS: 12 cases of endocarditis were treated with ceftobiprole, 11/12 in combination with daptomycin and 1/12 as monotherapy. Gram-positive bacteria were isolated in 12/12 patients; 3 cases were polymicrobial. Cure rate was 83% (10/12 patients). In 9/12 (75%) cases, patients were switched to ceftobiprole following failure of previous antimicrobial regimen. In 3/3 patients in which ceftobiprole was administered because of persistently positive blood culture, bacteraemia clearance was rapidly achieved. CONCLUSIONS:Ceftobiprole, especially in combination, could be a promising alternative treatment for infective endocarditis.